Navigation Links
New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF
Date:6/30/2009

on in patients undergoing infertility management, it is believed that it will have a major implication on the decision-making process when choosing the appropriate gonadotropin for ovarian stimulation.[1]

"I think the cost-effectiveness of treatments is a real issue for couples considering infertility treatment such as IVF today", says Clare Lewis-Jones from Infertility Network UK. "Despite the economic downturn, we see that couples will somehow find the money for treatment, although many have to make sacrifices in order to do this - it's a question of priorities and the opportunity of having a family is an extremely high priority for infertile couples."

MENOPUR

MENOPUR belongs to a class of drugs known as gonadotropins and contains both FSH (follicle stimulating hormone) and hCG-driven (human chorionic gonadotropin) LH-activity (luteinizing hormone). HP-hMG is used to stimulate the development of multiple follicles in women participating in an ART programme. HP-hMG is also used to treat infertility in women caused by anovulation (low-level production of eggs). MENOPUR is used by over 75,000 patients each year and is currently licensed in over 50 countries across the world

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring's fertility portfolio of treatments gives infertile couples the chance to have babies and includes its flagship brand MENOPUR (HP-hMG), a recognised high quality treatment for infertility. Ferring has operating subsidiaries in over 45 countries. To learn more about Ferring or our products please visit http://www.ferring.com.

References:

1. Wex
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
2. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
6. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
7. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
11. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... February 23 BN,ImmunoTherapeutics, Inc. today provided updated ... vaccine, MVA-BN(R)-HER2, in development as,therapy of metastatic breast ... its primary endpoint with regards to safety and ... immune response was,detected in approximately 70% of evaluated ...
... An international team of,researchers has evaluated ... the knee, and the results have been ... journal "Osteoarthritis and Cartilage".,The researchers followed 376 ... treatments. After six months as well as ...
Cached Medicine Technology:BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 2BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 3New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years 2
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... bottom of Alzheimer,s disease has been a rapidly ... In the latest crook in the research road, ... interaction between proteins associated with the disease. The ... Chemical Neuroscience , could have important implications for ... Nieznanski and colleagues explain that for years, research ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to reduce ... as 50 percent. When coupled with an innovative electrode ... device facilitated the complete elimination of seizures in nearly ... decade-long clinical trials. , That,s good news for a ... U.S. living with epilepsy whose seizures can,t be controlled ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... April 22, 2014: The Association for Molecular Pathology ... Journal of Molecular Diagnostics on recommendations for ... and master,s levels of education. The report was ... Task Force of the AMP Training and Education ... need of educating future medical laboratory scientists appropriately ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... , ... firm Jackson & Coker ranked #3 on SIA’s 2009 list of “Ten Best Staffing ... , ... December 11, 2009 -- Each year, Staffing Industry Analysts, a premier research and analysts ...
... The Phoenix Business Journal and BestCompaniesAZ, co-founders ... SCAN Health Plan Arizona has been named to the 2009 ... employees, who provided extensive insight into employee life. , SCAN ... culture and work environment that fosters personal and professional growth ...
... estrogen-positive tumors, study found , THURSDAY, Dec. 10 ... tamoxifen can boost survival in postmenopausal women with ... as estrogen receptor-positive, and it,s best given before ... study. , "Chemotherapy with Adriamycin adds to your ...
... , U.S. Rep. Gerry Connolly (D-Va.) Also to ... 10 The Federal Employees Health Benefits Plan (FEHBP) open enrollment period ... (AFGE) "Inside Government" radio program. The show will air on Friday, ... www.federalnewsradio.com and 1500 AM in the ...
... , DETROIT, Dec. 10 African-American political leaders, ... Monday, December 14th to create and implement a ... African-American Community. , "Detroit is leading the nation ... the Rev. Horace Sheffield III, National Board Member and ...
... to prevent recurrence, researchers find , THURSDAY, Dec. 10 ... millions of women to fight osteoporosis also cut the ... a dual role in keeping women healthy. , ... of breast cancer therapy. Our feeling is that bisphosphonates ...
Cached Medicine News:Health News:Jackson & Coker Ranks #3 among “Ten Best Staffing Firms to Work For” 2Health News:Jackson & Coker Ranks #3 among “Ten Best Staffing Firms to Work For” 3Health News:Jackson & Coker Ranks #3 among “Ten Best Staffing Firms to Work For” 4Health News:SCAN Health Plan Arizona Named one of Area's Best Places to Work by the Phoenix Business Journal and BestCompaniesAZ, LLC 2Health News:Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients 2Health News:Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients 3Health News:FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government' 2Health News:Black Community Unites Against HIV/AIDS Epidemic 2Health News:Bone Drugs May Beat Back Breast Cancer 2
White Standard Girdle...
Black Spandex Above the Knee Compression Girdles with Contact Closure with Zipper...
Short Girdle, Mid-thigh, Front Closure...
Male Body Shaper, Front Closure...
Medicine Products: